Introduction
Haplotype diversity is a key to understanding population evolution as well as disease evolution. Heterogeneity in both linkage disequilibrium (LD) and haplotype frequencies across the genome have been observed among large numbers of diverse ethnic populations in several studies. [1] [2] [3] [4] Earlier studies from our laboratory have shown that haplotype and LD patterns at different genes associated with diseases vary widely across different populations of the world. 2, [5] [6] [7] Studies on different genes associated with disease that included the Centre d'Etude du Polymorphisme Humain (CEPH) diversity panel have also shown widely varying haplotype patterns. 8, 9 These earlier studies demonstrate the importance of studying the variation patterns in multiple populations representing different regions of the world for genes that have been associated with disease. Cytochrome P450 2E1 (CYP2E1) is a member of the cytochrome P450 multifamily of enzymes that play a central role in activating and detoxifying a wide variety of xenobiotics as well as endogenous compounds. Several drug effects have been identified. The antifungal drug miconazale has been found 10 to inhibit CYP2E1 enzyme activity. Peterson et al. 11 have discussed the complex role CYP2E1 appears to play in the pharmacologic interaction of ciprofloxacin and pentoxifylline; genetic variation in CYP2E1 function may thus have complex secondary consequences. The review by Gonzalez and Yu 12 summarizes the evidence for the important role that genetic variation in the CYP2E1 enzyme plays in the susceptibility of patients to hepatitis induced by antituberculosis drug therapy. The PharmGKB database has links to publications showing the relationship to alcohol-related liver diseases and also reports drug response studies involving CYP2E1 for acetaminophen, alcohol, ethanol, geldanamycin and xenobiotics.
Considerable variation in allelic distributions at CYP2E1 and of CYP2E1 enzyme activity is found among different human populations. [13] [14] [15] [16] Several polymorphic sites in the 5 0 -flanking and intronic region of CYP2E1 have been reported to be associated with increased risk factors for cancers and other diseases. [16] [17] [18] [19] [20] However, no consistent results were observed in studies of the effects of these singlenucleotide polymorphisms (SNPs) on the expression of the gene and activity of the enzyme, and on the susceptibility to diseases. [21] [22] [23] [24] The promoter region and other regulatory variation in or near the gene will function in cis with any amino-acid variation as one functional unit. Relevant variation can also include any variants that affect splicing or mRNA conformation. Thus, the haplotype encompassing all relevant variation is the relevant unit for association studies. LD may allow SNPs with no functional consequences to serve as surrogates for unknown and/or untyped variants with functional consequences. However, haplotype frequencies and LD patterns are expected to vary among populations.
Haplotypes and LD of the CYP2E1 gene region have been poorly studied. The aim of the present study has been to analyze polymorphisms across most of the CYP2E1 gene, document global ethnic variation in their allelic frequencies and study the patterns that exist in haplotypes and LD. To those ends we present data on 11 polymorphisms, their frequencies and haplotypes in over 2600 normal, healthy individuals from 50 population samples representing all major geographical regions of the world.
Results
A total of 2657 mostly unrelated individuals (by self report) were typed and analyzed for each of these polymorphisms. Allele frequencies and sample sizes for the 11 polymorphisms in all 50 populations can be found in ALFRED (http:// alfred.med.yale.edu/) using the unique identifiers (UIDs) in Tables 1 and 2 . Allele frequency ranges for each polymorphism are given in Figure 1 , and the ancestral allele frequencies for the 10 SNPs and the most common allele frequency for the variable number of tandem repeats (VNTRs) are given in Supplementary Table S1 . There were no significant deviations from Hardy-Weinberg (HW) ratios. The average heterozygosities across 50 population samples and F st values for 11 markers are shown in Supplementary Figure S1 . For most markers the average heterozygosities are low, ranging from 0.035 (marker 7) to 0.283 (marker 10). F st values vary around the mean of 0.14 for a standard set of 369 SNPs 25 but are high at markers 10 and 11, 0.254, 0.231, respectively, at the 3 0 end of the gene. Only seven of the eleven markers segregate in all populations. The derived allele frequencies of SNPs at exon 4 (marker 6) and exon 6 (marker 7) are very low outside of Africa and these derived alleles are completely absent in the populations of East Asia and the Americas. The derived alleles of the upstream SNPs, except rs6413420 (marker 5), are observed in higher frequencies in Asia and the Americas than in Africa or Europe. We inferred 16 common haplotypes and estimated their frequencies ( Figure 2) . Most of the low-frequency variation in the residual class of rare haplotypes is accounted for by a relatively small number of haplotypes in the 2-4% frequency range. The variation in haplotype frequencies among populations gives rise to a complex pattern of LD, both pairwise and as segments with high LD, that varies among populations (Supplementary Table S2 and Figure S2 ).
Haplotype diversity is much higher in Africa (with 6-10 common haplotypes) than outside of Africa (with about 1-6 common haplotypes). The most common 11-marker haplotype, 6GCAGGCATCC (dark green in Figure 2 In order to understand the evolution of the haplotypes we estimated haplotypes with fewer SNPs across shorter segments of the gene. We identified three core regions that have evolved common haplotypes solely by accumulation of mutations from the ancestral core haplotype. These cores involve markers 1 through 5 (core A), markers 6 through 9 (core B), and markers 10 and 11 (core C; Figure 3) . No recurrent mutations are required to explain all of these core haplotypes. The full 11-marker haplotypes can be explained by combinations of the haplotypes of the three cores ( Figure  4 ; Supplementary Table S3 ). These combinations have arisen by accumulation of mutations (as depicted in Figure 3 ) and historical crossovers. It is difficult to be certain of orders of all events, mutations and crossovers, when the three cores are considered together, in part because other combinations that could have been intermediate now are either absent or exist among the rare haplotypes.
In contrast to the global frequency patterns of the whole 11-marker haplotypes, the individual core haplotypes show different global patterns (Supplementary Figures 3-5) . Core A haplotypes show greater frequency similarity between African and European populations than between European and both East Asian and Native American populations. One core A haplotype, 6GCAG (no. 1 in Figure 3a) , exists at frequencies of 56-95% in the Africans and Europeans. Another core A haplotype, 6CTAG (no. 5 in Figure 3a) , is not seen in Africans, is rare in Europeans, but is frequent in East Asian and Native American populations. To the degree these 5 0 markers encompass the major regulatory regions, it is possible that East Asians and Native Americans may have a common derived variant in regulation that is very uncommon to absent in the rest of the world.
Discussion
We are unaware of any publications of the CYP2E1 gene that have included all of the polymorphisms that we present here. Certainly, none of these markers has been studied previously on such a large and ethnically diverse set of individuals. This study is an explicit example of the type of global perspective on pharmacogenetic variation within and among populations discussed in an editorial by Marsh. 26 Even this data set does not probe the full extent of the genetic diversity of this small segment of DNA. Public databases report multiple additional polymorphisms across the gene (including 5 0 and 3 0 -untranslated regions). We cannot precisely relate the 16 common haplotypes (Figure 2) we have observed to the standard CYP2E1 allelic designations in the 'cypalleles' Web site (http://www.cypalleles.ki.se/cyp2e1.htm) because, from a genetic transmission perspective, each of the haplotypes we report is an allele and the 'cypalleles' Web site does not give full haplotype specifications for the allele designations they summarize, precluding a strict comparison. Moreover, we have not included SNPs with rare or uncommon variants that have not been studied widely. To distinguish the haplotypes we have identified from those in the 'cypalleles' nomenclature, we have used letter designations rather than numbers in Figures 2 and 4 and Supplementary Table S3 . As an example of the difficulty of establishing precise correspondences, the mutation G-A at marker 6 (corresponding to 179 Val-Ile) defines core B haplotype 4 ( Figure 3B ) and appears to represent one mutational event. That core B haplotype exists in two combinations with core A haplotypes and two combinations with core C haplotypes for a total of three Table 1 . Both the full allelic description and lower case letter codes for the haplotypes are given. For each population the proportional length of each color bar represents the frequency of the respective haplotype. All haplotypes that have frequencies less than 5% in all the populations studied are grouped into the residual (gray bar) class. The ancestral haplotype, GCAGGCAAGC, for markers 2 through 11, is not found at common frequencies in any of the 50 populations studied.
11-marker haplotypes: g, k and n (Figures 2 and 4 ). All three of these haplotypes correspond to allele CYP2E1*4 in the 'cypalleles' nomenclature. We expect the haplotypes encompassing the gene to become more complex as more SNPs and rare variants are included in an even more comprehensive study of the gene. In addition to multiple SNPs across this gene, copy number variation (CNV) encompassing CYP2E1 has been reported. 27, 28 Our typing methods are not designed to detect CNVs but we can exclude any common occurrence in our samples because there is no significant deviation from HW ratios in any of the populations.
We have studied the allele, haplotype and LD variation patterns for 11 polymorphisms in 50 populations from different geographical regions of the world across the CYP2E1 gene and have shown that there are large differences in these patterns worldwide. The haplotypes were useful in inferring recombination events in the recent evolution of the gene. The current study focuses attention on the core haplotype lineages that appear to have involved no recombination and on the combinations that have arisen because of historical recombinations. These cores and their combinations provide the framework for future expression studies. Depending upon when in one of the evolutionary lineages a functional variant arose, we would expect it to either define a new sublineage or be inherited into the descendant haplotypes in Figure 3 . Thus, the evolutionary lineages may explain multiple haplotypes (alleles) having similar functional properties, even if the causative variant has not yet been identified. Other SNPs within the molecular extent of the region spanned will likely fall within this framework; some might refine the locations of the inferred historical crossovers.
Supplementary information is available at the The Pharmacogenomics Journal's Web site. 
Materials and methods
Samples studied DNA was purified from lymphoblastoid cell lines from 2657 healthy adults from 50 populations from around the world (Table 2) . Population membership was designated by the subjects and all blood samples were obtained with individual informed consent following protocols approved by the Institutional Review Boards at Yale University School of Medicine, at the University of Karachi, and at multiple other relevant institutions in countries where samples were collected. The average population sample size is 53 individuals.
Markers studied
We studied 10 SNPs and 1 VNTR across 13.9 kb that encompasses the 5 0 region of the CYP2E1 gene and almost the entire coding region ( Figure 5 ). We typed the VNTR and four SNPs in the upstream region, three SNPs in the coding regions and three SNPs in the intronic regions of the gene ( Table 1 ). The markers are referred to by their numeric position (1-11) in Table 1 . The SNPs are all diallelic and the VNTR is essentially diallelic, as initially described.
29 Two other very rare VNTR alleles have been seen in some African populations in the course of this study (data not shown); they were excluded from the haplotype analyses.
Typing methods
The samples were typed by TaqMan assays (markers 2, 4-8, 10 and 11), by fragment length analysis on agarose gels (marker 1) after PCR, and by restriction fragment length after enzyme digestion of the PCR products for markers 3 (RsaI) and 9 (DraI).
Determining ancestral alleles
For each allele, the ancestral state in humans was determined by inference from the allele present in several other primate species. The ancestral allele of the VNTR (marker 1) could not be determined but by inference is 6.
Statistical methods
Allele frequencies of the VNTR and SNPs were calculated by gene counting assuming codominant inheritance. All the sites were also tested for Hardy-Weinberg (HW) ratios by w 2 -test and/or exact test. Expected heterozygosities were estimated as 1À P p i 2 . Haplotype frequencies were estimated by the expectation-maximization (EM) algorithm using HAPLO. 30 Haplotypes with estimated frequencies of less than 5% in each of the population samples go into the residual class. The 5% threshold is a reasonable boundary for determining what are the common and rare haplotypes given the sample sizes in this study. Although some estimated haplotypes below the 5% threshold have very clear evidence of occurrence, the standard errors on estimated frequencies increase along with some erroneous inferences due to the small number of observations available in the rare zone and the fact that the LD levels between sites vary. Pairwise LD estimates were carried out as r 2 31,32 with significance levels determined by a permutation test. 33 Comparative plots of LD for all the populations were carried out using HAPLOT. 34 
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